QIAGEN Marseille acquires exclusive rights from Inserm Transfert SA and Inserm on HSP110 mutations for colorectal cancer

Marseille, January 7, 2013 – QIAGEN Marseille, previously IPSOGEN (Alternext – FR0010626028 – ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for cancers, and an affiliate of QIAGEN, today announces the signature of an agreement with Inserm Transfert for a worldwide license on mutations of the HSP110 gene.

Detection of HSP110 mutations will enable physicians to identify so-called Microsatellite Instability (MSI), a genetic abnormality which occurs in around 15% of all Colorectal Cancers (CRC). MSI arises as a result of defective Mismatch Repair (MMR1 ) caused by the failure of one of the four main MMR genes, MSH2, MLH1, MSH6, or PMS2. MSI patients have a more favorable outcome and a different response to chemotherapeutic agents. Moreover, approx. one third of these MSI CRC cases correspond to Lynch syndrome, an inherited form of CRC for which making an accurate diagnosis is important since they have a higher risk of developing a second cancer.

Download Press Release